Weight changes are reported with many antidepressants. Lexapro is more commonly associated with weight loss or neutral weight effects, but some patients may experience modest weight gain over long-term use. Monitoring body weight during treatment is advisable.
Escitalopram crosses the placenta. The UK MHRA classifies it as Category B (no proven risk in animal studies, limited human data). The decision to continue during pregnancy should balance potential benefits against uncertain fetal risks and be made with obstetric input.
Most patients notice an improvement in mood or anxiety within 1-2 weeks, but the maximal therapeutic benefit often requires 4-6 weeks of consistent dosing.
Alcohol does not directly interfere with escitalopram’s metabolism, but it can worsen depressive symptoms and increase drowsiness. Moderate consumption is generally acceptable, but excessive drinking should be avoided.
If you remember within 12 hours, take the missed dose now. If more than 12 hours have passed, skip it and resume your regular schedule the following day. Do not take a double dose.
Common analgesics such as paracetamol and ibuprofen have no major interaction with escitalopram. However, non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal bleeding, especially when combined with SSRIs.
Key symptoms include agitation, rapid heart rate, high fever, sweating, dilated pupils, muscle rigidity, and tremor. If these occur, seek emergency medical care immediately.
Combining SSRIs with other serotonergic agents (e.g., other antidepressants, triptans) raises the risk of serotonin syndrome and is generally avoided unless specifically directed by a specialist.
Carry the medication in its original packaging, keep it in a carry-on bag to avoid temperature extremes, and ensure you have a copy of the prescription. If staying longer than six months, check local regulations for bringing prescription medicines into the destination country.
Lexapro is a prescription medication that contains the active ingredient escitalopram, a selective serotonin reuptake inhibitor (SSRI) belonging to the antidepressant class. It is supplied as a pill in strengths of 5 mg, 10 mg, and 20 mg. In the United Kingdom, Lexapro is approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and is typically prescribed for adult patients with major depressive disorder and generalized anxiety disorder. It is marketed by Lundbeck, a pharmaceutical company that provides the product throughout the UK.
Escitalopram belongs to the SSRI family. Its primary action is to block the re-uptake of serotonin (5-hydroxytryptamine) into presynaptic neurons. By inhibiting this transporter, more serotonin remains available in the synaptic cleft, enhancing serotonergic neurotransmission. The increased serotonin activity helps to stabilize mood, reduce anxiety, and improve emotional regulation.
Key pharmacokinetic points:
Lexapro is MHRA-approved for the following adult indications:
These indications are supported by robust clinical trials demonstrating efficacy in symptom reduction and functional improvement. Lexapro is generally prescribed for adults; use in children and adolescents requires special consideration and is not covered by the UK license for these conditions.
Research and clinical guidelines have explored several off-label applications of escitalopram. Where evidence exists, each use is not approved by the MHRA and should be considered only under specialist supervision:
Disclaimer: Off-label use requires individualized risk assessment and close monitoring by a qualified healthcare professional.
This article provides educational information about Lexapro and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
